T. Rowe Price Associates’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $188M | Sell |
|
|||||
|
2025
Q1 | $479M | Sell |
|
|||||
|
2024
Q4 | $495M | Buy |
|
|||||
|
2024
Q3 | $498M | Sell |
|
|||||
|
2024
Q2 | $633M | Sell |
|
|||||
|
2024
Q1 | $593M | Buy |
|
|||||
|
2023
Q4 | $501M | Sell |
|
|||||
|
2023
Q3 | $276M | Sell |
|
|||||
|
2023
Q2 | $355M | Buy |
|
|||||
|
2023
Q1 | $223M | Buy |
|
|||||
|
2022
Q4 | $188M | Buy |
|
|||||
|
2022
Q3 | $266M | Sell |
|
|||||
|
2022
Q2 | $284M | Buy |
|
|||||
|
2022
Q1 | $315M | Buy |
|
|||||
|
2021
Q4 | $487M | Buy |
|
|||||
|
2021
Q3 | $449M | Buy |
|
|||||
|
2021
Q2 | $375M | Buy |
|
|||||
|
2021
Q1 | $394M | Buy |
|
|||||
|
2020
Q4 | $414M | Buy |
|
|||||
|
2020
Q3 | $331M | Sell |
|
|||||
|
2020
Q2 | $280M | Buy |
|
|||||
|
2020
Q1 | $210M | Buy |
|
|||||
|
2019
Q4 | $269M | Sell |
|
|||||
|
2019
Q3 | $265M | Sell |
|
|||||
|
2019
Q2 | $347M | Buy |
|
|||||
|
2019
Q1 | $270M | Buy |
|
|||||
|
2018
Q4 | $163M | Buy |
|
|||||
|
2018
Q3 | $225M | Sell |
|
|||||
|
2018
Q2 | $198M | Sell |
|
|||||
|
2018
Q1 | $318M | Buy |
|
|||||
|
2017
Q4 | $250M | Buy |
|
|||||
|
2017
Q3 | $191M | Buy |
|
|||||
|
2017
Q2 | $125M | Buy |
|
|||||
|
2017
Q1 | $80.6M | Buy |
|
|||||
|
2016
Q4 | $20.7M | Buy |
|
|||||
|
2016
Q3 | $10.5M | Sell |
|
|||||
|
2016
Q2 | $12M | Buy |
|
|||||
|
2016
Q1 | $9.24M | Sell |
|
|||||
|
2015
Q4 | $14.1M | Buy |
|
|||||
|
2015
Q3 | $10.6M | Sell |
|
|||||
|
2015
Q2 | $13.3M | Buy |
|